Extended Data Fig. 1: Phenotype and potency of APCs.
From: Sensitive identification of neoantigens and cognate TCRs in human solid tumors
a, Representative profiling of viable CD40-act B. Ex vivo peripheral CD19 cells from a healthy donor (HD) were used as control. b, Comparison of the level of neoepitope-specific T cell stimulation obtained with CD40-act B cells loaded with different sources of antigen. Autologous CD40-act B cells were either pulsed with the minimal epitope, electroporated with RNA-encoding tandem minigene (TMG) or loaded with the 31mer. B cells were co-cultured with x1NeoScreen TILs from patient 7 (Supplementary Table 4). T cell reactivity to PHLPP2N1186Y was assessed by IFNγ ELISpot assay (n = 1 experiment, mean±SD of triplicate). MOCK: B cells transfected with PBS. c, CD40-act B cells electroporated with RNA encoding immune stimulatory molecules OX40L, 4-1BBL and IL-12 (Methods). Flow cytometry analysis of 4-1BBL and OX40L expression after electroporation of B cells from a representative patient (left). MSD measurement of IL-12p70 production by electroporated B cells (right, mean±SD of triplicate). MOCK: B cells transfected with PBS, NT: non-transfected, stim: stimulatory.
